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Abstract A live attenuated inﬂuenza vaccine (LAIV) is currently
approved in the United States for the prevention of inﬂuenza
in individuals 2–49 years of age. This article summarizes the
available data describing the safety and efﬁcacy of LAIV for the
prevention of inﬂuenza in both children and adults. LAIV is
administered as an intranasal spray and has been shown to
provide high levels of efﬁcacy against inﬂuenza illness caused by
both matched and mismatched strains in children and adults.
In studies comparing LAIV and inactivated inﬂuenza vaccine in
children, LAIV recipients experienced 35–53% fewer cases of
culture-conﬁrmed inﬂuenza illness caused by antigenically
matched strains. Protection through a second inﬂuenza season
against antigenically matched strains has also been seen in
children. In adults, deﬁnitive comparative studies of LAIV and
inactivated vaccine have not been conducted and no statistically
signiﬁcant differences in efﬁcacy have been demonstrated. The
most common adverse reactions with LAIV include runny nose/
nasal congestion in all age groups, fever >100 F in children,
and sore throat in adults. Formulations of LAIV against
pandemic inﬂuenza strains, including H5N1, H9N2, and H7N3,
are currently being tested in preclinical and phase I clinical
studies.
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Seasonal live attenuated inﬂuenza vaccine
Live attenuated inﬂuenza vaccine (LAIV; marketed in the
United States as FluMist
  [Inﬂuenza Virus Vaccine Live,
Intranasal]) was approved for use in the United States in
2003, becoming the ﬁrst nasally administered vaccine for
human use in the United States. The approval of LAIV was
the culmination of more than 30 years of collaborative
research and development by scientists from academia, the
National Institutes of Health (NIH), and the biopharma-
ceutical industry (MedImmune and Wyeth Vaccines). LAIV
is currently approved in the United States for use in indi-
viduals 2–49 years of age.
Live attenuated inﬂuenza vaccine was originally derived
by cold adaptation of an inﬂuenza type A strain (A/Ann
Arbor/6/60 H2N2) and a type B strain (B/Ann Arbor/1/66)
by serial passage at sequentially lower temperatures in spe-
ciﬁc pathogen-free primary chick kidney cells.
1 During this
process, the viruses acquired multiple mutations in internal
protein gene segments (i.e., genes encoding ‘‘internal’’ non-
glycosylated proteins) that produced the cold-adapted (ca),
temperature-sensitive (ts), and attenuated (att) phenotype
of the master donor viruses (MDVs). The MDVs represent
the LAIV genetic backbone that is updated annually with
hemagglutinin (HA) and neuraminidase (NA) genes from
contemporary inﬂuenza viruses to produce the annual tri-
valent formulation.
The individual contributions of the genetic sequences of
the six internal gene segments to the ca, ts, and att phenotype
of the MDVs are not completely understood, but many of
the mutations associated with the phenotypes have been
identiﬁed (Table 1). For the type A MDV, at least ﬁve genetic
loci in three different internal protein gene segments contrib-
ute to the ts and att phenotypes.
2,3 For the type B MDV, at
least three genetic loci in two different gene segments con-
tribute to both the ts and att properties; two additional loci
in a third gene segment also contribute to the att property;
ﬁve loci in three segments control the ca property.
4,5
Because multiple loci in several genes control the ca, ts,
and att phenotypes of LAIV vaccine viruses, it is highly
improbable that LAIV would lose these phenotypes as a
result of reversion.
6,7 Given the error rate of 10
)4 to 10
)5
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virus replication and the fact that at least ﬁve point muta-
tions are responsible for the attenuated properties of each
MDV,
7,8 the probability of a LAIV vaccine virus reverting
to wild-type inﬂuenza, with mutations in the ﬁve attenuat-
ing loci, would be one in at least 10
20 replication cycles. In
one study of 135 vaccine strains recovered from young vac-
cinated children, no evidence of reversion was observed.
9
Each of the three inﬂuenza virus strains contained in LAIV
is a 6:2 genetic reassortant virus, containing six internal gene
segments from ca, ts, and att MDVs and two gene segments
(encoding the HA and NA proteins) from a wild-type inﬂu-
enza virus that is selected annually by the World Health
Organization and the US Public Health Service. Genetic reas-
sortant viruses are prepared using reverse genetics technol-
ogy in cell culture, a technique whereby inﬂuenza viruses can
be generated from DNA plasmids containing inﬂuenza genes
(Figure 1). LAIV vaccine viruses were originally generated
using classical reassortment, but in 2008 the process transi-
tioned to reverse genetics technology.
Three vaccine strains are formulated together to produce
a trivalent LAIV vaccine in single-dose sprayers. Bulk vac-
cine is currently produced in speciﬁc pathogen-free embry-
onated hens’ eggs, and plans are ongoing to assess future
manufacture in cell culture. No preservatives are used in
the manufacture of LAIV.
Mechanism of action
Live attenuated inﬂuenza vaccine viruses replicate primarily
in the ciliated epithelial cells of the nasopharyngeal mucosa
to induce immune responses (via mucosal immunoglobulin
[Ig]A, serum IgG antibodies, and cellular immunity), but
LAIV viruses do not replicate well at the warmer tempera-
tures found in the lower airways and lung.
7,10 During the
course of replication, all LAIV viral proteins would be pre-
sented to the immune system in their native conformation
and in the context of histocompatibility proteins; resultant
immune responses should mimic those of natural infection
with inﬂuenza virus.
Table 1. Phenotypic characteristics and phenotype-controlling genes for MDVs and vaccine reassortants
2–5
Phenotype Cold adaptation (ca) Temperature sensitivity (ts) Attenuation (att)
Characteristics of phenotype Efﬁcient growth at 25 C Restricted growth at 37 C
(type B) or 39 C (type A)
Restricted replication in ferret
respiratory tract; minimal to
no illness produced
Genes associated with indicated phenotype for each MDV
Type A MDV and vaccine strains Genes not identiﬁed PB2, PB1, NP PB2, PB1, NP
Type B MDV and vaccine strains PB2, PA, NP PA, NP PA, NP, M
LAIV, live attenuated inﬂuenza vaccine; MDV, master donor virus.
6:2 Vaccine seed strain 
Electroporate  Electroporate vero cells  Vero cells
HA and NA genes from   HA and NA genes from  
wild type for immunity  wild type for immunity 
6 genes from MDV   6 genes from MDV  
for   for   ca,   ca,  ts  ts  ,   ,  att  att 
PB1  PB1  NP  NP  PA 
PB2  PB2  M  NS 
HA  HA  NA  NA 
Plasmids containing   Plasmids containing  
wild  wild  -  -  type virus genes  type virus genes 
Plasmids containing   Plasmids containing  
MDV genes  MDV genes 
Figure 1. Schematic diagram of LAIV vaccine
seed strain preparation using reverse genetics.
Plasmids containing the MDV genes that
control ca, ts, and att phenotypes and wild-
type virus HA and NA genes are
electroporated into Vero cells to generate the
appropriate 6:2 vaccine strain. The 6:2 seed
strain is used to manufacture LAIV. att,
attenuated; ca, cold-adapted; HA,
hemagglutinin; LAIV, live attenuated inﬂuenza
vaccine; MDV, master donor virus; NA,
neuraminidase; ts, temperature sensitive.
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LAIV efﬁcacy relative to placebo
The efﬁcacy of LAIV relative to placebo has been exam-
ined in six studies in children aged 6–71 months
(Table 2); LAIV is currently approved for use in children
24 months and older. Following ﬁrst-year vaccination,
efﬁcacy against illness caused by antigenically matched
strains (A/H1N1, A/H3N2, and B) has ranged from
62Æ2% to 93Æ4%. In studies that assessed efﬁcacy in a
second season following revaccination, efﬁcacy ranged
from 73Æ6% to 100%. LAIV has also been shown to
reduce the incidence of all-cause febrile otitis media by
30–32% and inﬂuenza-associated otitis media by 73–98%
compared with placebo.
11–13
In addition to high levels of efﬁcacy against matched
strains, LAIV has shown protection against antigenically
mismatched strains. In year 2 of study AV006, LAIV dem-
onstrated 86% protection against the drifted variant A/Syd-
ney/5/97 (H3N2) strain.
14 Additionally, when an inﬂuenza
B variant circulated in 2000–2001, a single dose of LAIV in
children 1Æ5–18 years of age was estimated to provide 66%
(95% CI: 9, 87) protection in a large, nonrandomized,
open-label study (n = 2281).
15,16 During the 2003–2004
season, LAIV was estimated to have provided 56% (95%
CI: 24, 84) efﬁcacy against the mismatched A/Fujian/411/02
(H3N2) virus (n = 1706).
17
Although two doses of inﬂuenza vaccine are recom-
mended in previously unvaccinated young children, three
studies
11,13,18 compared one dose of LAIV with placebo in
this population. Efﬁcacy of a single dose was 58% (95%
CI: 45, 68), 60% (95% CI: 31, 77), and 89% (95% CI: 65,
96), respectively. Greater efﬁcacy is provided by two doses,
and thus two doses are recommended. However, given that
compliance with the two-dose regimen is low,
19 it is reas-
suring that a single dose of LAIV has provided clinically
signiﬁcant protection for vaccine-naive young children who
fail to receive a second dose.
With regard to duration of protection, in one placebo-
controlled study LAIV demonstrated protection during a
season in which inﬂuenza circulated for up to 13 months
following vaccination.
17 Additionally, two placebo-con-
trolled studies demonstrated that two doses of LAIV in
year 1 provided 56% (95% CI: 31, 73) and 57% (95% CI:
6, 82) protection through a second inﬂuenza season with-
out revaccination.
13,18
LAIV efﬁcacy relative to inactivated vaccine
Three studies have compared the efﬁcacy of trivalent inacti-
vated inﬂuenza vaccine (TIV) and LAIV in children aged
6–59 months, 6–71 months with a history of recurrent
respiratory tract infections, and 6–17 years with stable,
medically-treated asthma (Table 3). In these studies, LAIV
was more effective than TIV, reducing culture-conﬁrmed
inﬂuenza illness caused by matched strains by 35–53%.
20–22
Across the studies, signiﬁcant reductions were seen against
antigenically matched A/H1N1 and B strains as well as
antigenically mismatched A/H3N2 strains. LAIV also
reduced inﬂuenza-associated otitis media by 51% when
compared with TIV in Study MI-CP111.
22 Due to insufﬁ-
cient data, the current US prescribing information states
that LAIV should not be administered to any individuals
with asthma or children <5 years of age with recurrent
wheezing because of the potential for increased risk of
Table 2. LAIV efﬁcacy in placebo-controlled pediatric studies
Study number
(reference) Region
Age range,
months
Number of
subjects
Inﬂuenza
season
Efﬁcacy against inﬂuenza illness %
(95% CI)
Antigenically
matched strains
All strains
regardless of
antigenic match
AV006
11,14 United States 15 to <72 1602 1996 93Æ4 (87Æ5, 96Æ5) 92Æ6 (87Æ3, 95Æ7)
1997 100 (63Æ1, 100) 87Æ1 (77Æ7, 92Æ6)
D153-P501
18 Asia 12 to <36 3174 2000–2001 72Æ9 (62Æ8, 80Æ5) 70Æ1 (60Æ9, 77Æ3)
2001–2002 84Æ3 (70Æ1, 92Æ4) 64Æ2 (44Æ2, 77Æ3)
D153-P502
39 Europe 6 to <36 1784 2000–2001 85Æ4 (74Æ3, 92Æ2) 85Æ9 (76Æ3, 92Æ0)
2001–2002 88Æ7 (82Æ0, 93Æ2) 85Æ8 (78Æ6, 90Æ9)
D153-P504
13 South Africa, South America 6 to <36 3200 2001 73Æ5 (63Æ6, 81Æ0) 72Æ0 (61Æ9, 79Æ8)
2002 73Æ6 (33Æ3, 91Æ2) 46Æ6 (14Æ9, 67Æ2)
D153-P513
38 Asia 6 to <36 2172 2002 62Æ2 (43Æ6, 75Æ2) 48Æ6 (28Æ8, 63Æ3)
D153-P522
53 Europe, Asia, Mexico 11 to <24 1233 2002–2003 78Æ4 (50Æ9, 91Æ3) 63Æ8 (36Æ2, 79Æ8)
LAIV, live attenuated inﬂuenza vaccine.
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weighs the potential risk.
23
Efﬁcacy/effectiveness in adults
LAIV efﬁcacy in adults 18–64 years of age
Study AV009
24 was a randomized, double-blind, placebo-
controlled study in adults 18–64 years of age (n = 4561)
that evaluated the effectiveness of LAIV in preventing any
febrile illness (AFI), as well as more inﬂuenza-speciﬁc syn-
dromes such as severe febrile illness (SFI) and febrile upper
respiratory illness (FURI); prevention of inﬂuenza-like ill-
ness (ILI) as deﬁned by the Centers for Disease Control
and Prevention (CDC), and the US Department of Defense
(DOD) were analyzed post hoc. The study was conducted
during a season dominated by an antigenically mismatched
A/H3N2 strain. During the season, LAIV recipients had
9Æ7% fewer cases of AFI compared with placebo recipients
(not signiﬁcant). However, LAIV recipients experienced
statistically signiﬁcant reductions in SFI, FURI, CDC-ILI,
and DOD-ILI (Figure 2). Signiﬁcant reductions in illness
were seen for subjects <40 years of age as well as for sub-
jects ‡40 years of age. However, in a post hoc analysis of
adults 50–64 years of age (n = 641), effectiveness was not
demonstrated; as a result, LAIV is not approved for use in
the United States in adults 50 years of age and older.
From this study, which measured illness regardless of eti-
ology and did not include laboratory diagnosis of inﬂuenza
infection, it is not possible to generate an inﬂuenza-speciﬁc
efﬁcacy estimate. However, during the same season, the
CDC conducted a placebo-controlled study of inactivated
inﬂuenza vaccine in a similar population: healthy, working
adults 18–64 years of age (n = 1184).
25 Although no effec-
tiveness for inactivated vaccine was seen, results indicate
Table 3. LAIV efﬁcacy relative to TIV in active-controlled pediatric studies
Study number
(reference) Region Age range
Number of
subjects
Inﬂuenza
season
Relative efﬁcacy compared with TIV %
(95% CI)
Against matched
strains
Against all
strains regardless
of match
MI-CP111
22 North America,
Europe, Asia,
Middle East
6 to <60 months 8475 2004–2005 44Æ5 (22Æ4, 60Æ0) 54Æ9 (45Æ4, 62Æ9)
D153-P514
20 Europe, Israel 6 to <72 months* 2187 2002–2003 52Æ7 (21Æ6, 72Æ2) 52Æ4 (24Æ6, 70Æ5)
D153-P515
21 Europe, Israel 6 to <18 years** 2229 2002–2003 34Æ7( 3 Æ9, 56Æ0) 31Æ9( 1 Æ1, 53Æ5)
LAIV, live attenuated inﬂuenza vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
*The study population consisted of children with a history of recurrent respiratory tract infections.
**The study population consisted of children with stable, medically-treated asthma. Due to insufﬁcient data, the current US prescribing informa-
tion states that LAIV should not be administered to any individuals with asthma or children <5 years of age with recurrent wheezing because of
the potential for increased risk of wheezing post-vaccination unless the potential beneﬁt outweighs the potential risk.
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Figure 2. Effectiveness of LAIV in reducing
illness in adults 18–64 years of age (study
AV009). *P <0 Æ05;
 P <0 Æ001. CDC-ILI,
inﬂuenza-like illness as deﬁned by the Centers
for Disease Control and Prevention guidelines;
DOD-ILI, inﬂuenza-like illness as deﬁned by
the US Department of Defense guidelines;
LAIV, live attenuated inﬂuenza vaccine; URI,
upper respiratory tract illness.
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been caused by inﬂuenza (4Æ4% laboratory-conﬁrmed inﬂu-
enza, 23Æ8% CDC-ILI). If this ratio is applied to the rates
of CDC-ILI from study AV009 (data on ﬁle), the inﬂu-
enza-speciﬁc efﬁcacy for LAIV can be projected to have
been 75–94%.
The ﬁrst study to directly assess the efﬁcacy of the
licensed formulation of LAIV in adults was an experimental
challenge study. Among seronegative adults 18–40 years of
age (n = 103), LAIV demonstrated 85% (95% CI: 28, 100)
efﬁcacy against culture-conﬁrmed inﬂuenza illness;
26 the
efﬁcacy of TIV was estimated at 71% (95% CI: 2, 97).
Subsequently, investigators at the University of Michigan
initiated a 3-year study of the efﬁcacies of TIV and LAIV
compared with placebo in healthy adults 18–48 years of
age.
27 In year 1 (n = 1247), the absolute efﬁcacies of TIV
and LAIV against culture-conﬁrmed illness were 77% (95%
CI: 37, 92) and 57% (95% CI: )3, 82), respectively; results
for culture- or PCR-conﬁrmed illness were 75% (95% CI:
42, 90) and 48% (95% CI: )7, 74). The vaccines had simi-
lar efﬁcacy against inﬂuenza A/H3N2 but LAIV had lower
efﬁcacy against inﬂuenza B; this may have resulted from
poor immunity against inﬂuenza B or the chance occur-
rence of increased infections in LAIV recipients caused by
inﬂuenza B viruses from the alternate genetic lineage, given
that no inﬂuenza vaccine has demonstrated efﬁcacy against
cross-lineage B strains.
28,29 Analysis of results from year 2
of the study (2005–2006, n = 2058) were complicated by a
low inﬂuenza attack rate; efﬁcacies of the two vaccines were
similar and highly variable across different analysis
methods.
30
Another study described the efﬁcacy of LAIV and TIV in
young healthy adults (US military trainees) in 2005–2006.
31
Using a methodology that compared inﬂuenza incidence
within the 2 weeks following vaccination (before the devel-
opment of adaptive immune responses) to the incidence
2 weeks or more after vaccination, researchers concluded
that the overall efﬁcacy for the inﬂuenza vaccines was 92%
(95% CI: 85, 96); efﬁcacy was 95% at a site that used LAIV
exclusively.
LAIV experience in adults ‡50 years of age
Although LAIV is not approved for use in adults 50 years
or older, several studies have been conducted in adults
‡50 years of age; these data are presented below for
completeness.
In adults 60 years or older, two randomized controlled
studies have been conducted, one placebo-controlled and
one TIV-controlled. Study D153-P507 (n = 3242) was a
randomized, double-blind study conducted in South Africa
in 2001. LAIV efﬁcacy against antigenically matched strains
was 42Æ3% (95% CI: 21Æ6, 57Æ8) compared with placebo,
with 52Æ5% (95% CI: 32Æ1, 67Æ2) efﬁcacy against A/H3N2
and no efﬁcacy against inﬂuenza B (1Æ4% LAIV, 1Æ3% pla-
cebo).
32 Study D153-P516 (n = 3009) was a randomized,
open-label, TIV-controlled study conducted in South Africa
in 2002
33 from which no efﬁcacy conclusions could be
drawn because of the few cases of culture-conﬁrmed inﬂu-
enza illness. In these studies, rates of runny nose/nasal con-
gestion, cough, sore throat, headache, muscle ache,
tiredness, decreased appetite, and use of fever medication
were increased in LAIV recipients.
The efﬁcacy of LAIV in simultaneous combination with
TIV has also been studied in the elderly. In a double-blind
ﬁeld trial conducted over a 3-year period in nursing home
residents aged ‡65 years, 523 residents (mean age, 84 years)
received TIV and either monovalent A/H3N2 LAIV or pla-
cebo.
34 TIV+LAIV recipients experienced 61% (95% CI:
18, 82) fewer cases of laboratory-documented inﬂuenza A
compared with TIV+placebo. A later study with a monova-
lent B LAIV suggested a similar trend, but attack rates were
too low to allow deﬁnitive conclusions.
35 A third study was
conducted among 2215 individuals ‡50 years of age with
COPD within the Veterans Affairs medical system.
36 In this
study, the relative efﬁcacy of TIV+LAIV compared with
TIV+placebo in the prevention of laboratory-documented
inﬂuenza illness was 16% (95% CI: )22, 43) for any inﬂu-
enza strain, 26% (95% CI: )17, 53) for A/H3N2, and )5%
(95% CI: )113, 48) for B. However, TIV+LAIV recipients
were shown to have an improvement in chronic lung dis-
ease severity index scores over the course of the study.
37
TIV+LAIV recipients reported higher rates of increased
sputum, stuffy/runny nose, increased shortness of breath,
chills, and itchiness at the intramuscular injection site com-
pared with TIV+placebo recipients.
Role of antibody responses to LAIV in
predicting protection
It is important to note that, unlike TIV, no general
immune correlates of protection have been established for
LAIV. Serum antibody responses, mucosal antibody
responses, and cellular responses have been observed in
vaccine recipients; one study in young children demon-
strated a correlation between interferon-gamma ELISPOT
responses and protection from culture-conﬁrmed inﬂuenza
illness.
38 However, no similar correlation has been seen for
serum antibody responses. Serum antibody responses are
generally only detected in individuals with low titers of
pre-existing serum antibody. Overall, studies have demon-
strated that the proportion of individuals experiencing
at least a fourfold rise in serum HA inhibition (HAI)
antibody titer is often correlated with protective efﬁ-
cacy
11,18,39,40; however, studies have also shown protection
in the absence of signiﬁcant antibody responses.
26,41 In the
challenge study in healthy adults described above, LAIV
Seasonal and pandemic LAIV
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the fact that only 24% of LAIV recipients experienced a
‡4-fold rise in HAI titer following vaccination. Interest-
ingly, this study also suggested that serologic endpoints in
inﬂuenza vaccine efﬁcacy trials may underestimate
inﬂuenza infections in TIV recipients (thus overestimating
efﬁcacy) because none of the four TIV recipients who
developed inﬂuenza illness after wild-type challenge experi-
enced a ‡4-fold rise in HAI titer with illness (pre-challenge,
post-vaccination titers were <4, 32, 128, and 128).
LAIV safety proﬁle
The safety of LAIV has been evaluated in approximately
49 000 individuals in 48 completed studies, including more
than 18 000 children younger than 5 years. Additionally,
more than 10 million doses have been commercially dis-
tributed in the United States since licensure. In clinical
studies, the most common adverse reactions (‡10% in
LAIV recipients and at least 5% greater than in controls)
were runny nose or nasal congestion in all ages, fever
>100 F in children 2–6 years of age, and sore throat in
adults (Tables 4 and 5).
23 Rates of reactogenicity events
generally decline upon revaccination with LAIV, either in
the same or subsequent seasons.
Study MI-CP111
22 was prospectively designed to evaluate
wheezing in children 6–59 months of age. The incidence of
medically signiﬁcant wheezing (MSW) was analyzed
through 42 days after vaccination with LAIV or TIV; MSW
was deﬁned as a medical diagnosis of wheezing associated
with other respiratory ﬁndings (e.g., hypoxemia, respiratory
distress, or initiation of daily bronchodilator therapy).
MSW was reported in more subjects 6–23 months of age
who had received LAIV than in those given TIV (LAIV,
5Æ9%; TIV, 3Æ8%; P =0 Æ002). Among children aged 24–
59 months, rates of MSW were comparable in LAIV and
TIV recipients (LAIV, 2Æ1%; TIV, 2Æ5%; P =0 Æ38). In this
same study, hospitalization rates were higher in LAIV
recipients 6–23 months of age compared with TIV recipi-
ents (4Æ2% versus 3Æ2%, P =0 Æ09) with no increase among
children 24–59 months of age (2Æ1% versus 2Æ5%;
P =0 Æ33). The increase in hospitalizations in children
<2 years was driven by children 6–11 months of age (LAIV,
6Æ1%; TIV, 2Æ6%; P =0 Æ002) and most of the hospitaliza-
tions occurred >42 days after the last dose, were not tem-
porally clustered, and were accounted for by events
commonly expected in this population (e.g., respiratory
tract and gastrointestinal tract infections). A biological
rationale for this increase in late-occurring hospitalizations
cannot be readily explained. In older subgroups of children
12–23 and 24–59 months of age, hospitalization rates were
not increased in LAIV versus TIV recipients.
In the University of Michigan multi-year comparative
study of LAIV and TIV in adults <50 years of age,
27,30 year
Table 4. Incidence of reactogenicity events within 10 days after administration of doses 1 and 2 of LAIV or placebo to children 2–6 years of age
(studies AV006, D153-P501)
Reactogenicity
events, n/N (%)
Dose 1 Dose 2
LAIV
(n = 876–1759)
Placebo
(n = 424–1034) P
LAIV
(n = 702–1490)
Placebo
(n = 330–868) P
Runny/stuffy nose,
nasal congestion
1022/1759 (58Æ1) 513/1034 (49Æ6) <0Æ001 717/1490 (48Æ1) 378/868 (43Æ5) 0Æ032
Sore throat 93/879 (10Æ6) 37/425 (8Æ7) 0Æ324 46/702 (6Æ6) 25/331 (7Æ6) 0Æ598
Cough 522/1757 (29Æ7) 351/1029 (34Æ1) 0Æ016 525/1488 (35Æ3) 280/866 (32Æ3) 0Æ150
Vomiting 161/1754 (9Æ2) 113/1028 (11Æ0) 0Æ130 132/1485 (8Æ9) 72/864 (8Æ3) 0Æ704
Headache 82/879 (9Æ3) 30/424 (7Æ1) 0Æ205 41/702 (5Æ8) 22/331 (6Æ6) 0Æ676
Muscle aches 53/878 (6Æ0) 12/424 (2Æ8) 0Æ014 22/702 (3Æ1) 7/330 (2Æ1) 0Æ424
Chills 39/878 (4Æ4) 14/424 (3Æ3) 0Æ372 23/703 (3Æ3) 12/331 (3Æ6) 0Æ854
Decreased activity (lethargy) 254/1755 (14Æ5) 108/1028 (10Æ5) 0Æ003 148/1489 (9Æ9) 84/866 (9Æ7) 0Æ886
Irritability 366/1755 (20Æ9) 190/1029 (18Æ5) 0Æ141 205/1487 (13Æ8) 119/864 (13Æ8) >0Æ99
Decreased appetite 188/876 (21Æ5) 105/604 (17Æ4) 0Æ055 113/783 (14Æ4) 99/534 (18Æ5) 0Æ048
Use of fever medication 168/876 (19Æ2) 101/604 (16Æ7) 0Æ244 91/783 (11Æ6) 72/534 (13Æ5) 0Æ349
Fever
>100 F oral or equivalent 281/1744 (16Æ1) 114/1020 (11Æ2) <0Æ001 156/1466 (10Æ6) 82/858 (9Æ6) 0Æ436
>101 F oral or equivalent 124/1744 (7Æ1) 53/1020 (5Æ2) 0Æ053 76/1466 (5Æ2) 46/858 (5Æ4) 0Æ848
>102 F oral or equivalent 51/1744 (2Æ9) 25/1020 (2Æ5) 0Æ547 41/1466 (2Æ8) 20/858 (2Æ3) 0Æ591
LAIV, live attenuated inﬂuenza vaccine. n, number of subjects reporting the event; N, number of evaluable subjects (those who returned diary
cards) for each event. Range in N reﬂects differences in data collection between the two pooled studies.
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soreness in TIV recipients and increased rates of runny
nose/congestion, cough, and headache in LAIV recipients.
In year 2, TIV recipients had increased rates of arm sore-
ness, arm redness, muscle aches, as well as trouble breath-
ing and red eyes (reported in other studies as ocular
respiratory syndrome); LAIV recipients had increased rates
of sore throat and runny nose/congestion.
The vaccine viruses in LAIV replicate in the cells of the
nasal mucosa and can at times be isolated from nasal secre-
tions post-vaccination. Based on two prospective studies,
shedding of vaccine virus on at least 1 day is frequent in
young children (e.g., 89% and 69% of subjects aged 6–23
and 24–59 months, respectively) and decreases with
advancing age (44%, 27%, and 17% in individuals aged
5–8, 9–17, and 18–49 years, respectively).
42,43 In these stud-
ies, peak shedding incidence occurred on day 2, with the
average subject with shedding having virus recoverable for
1Æ5–3 days and with titers below 1Æ5 log10 TCID50/ml after
13, 10, and 6 days post-vaccination for individuals
6–23 months, 2–8 years, and ‡9 years of age.
Based on available information, transmission of vaccine
virus from a vaccine recipient to an unvaccinated contact
is likely to be a rare event, even in young children, and
without negative clinical consequences. In a daycare study
in children (n = 98) designed to optimize the occurrence
and detection of transmission, one documented case of
transmission was observed. The transmitted type B vaccine
strain was only detected on 1 day, retained its ca, ts pheno-
type, and did not cause disease. Based on this study, the
probability of transmission to a child following daycare
contact with a single vaccinated child was calculated to be
0Æ58%.
9 Four additional type A strains from placebo
recipients could not be characterized as vaccine or wild-
type; inclusion of these four isolates as possible cases yields
a transmission probability of 2Æ4%.
23
Live attenuated inﬂuenza vaccine is not approved for use
in immunocompromised individuals. However, because of
concerns regarding inadvertent exposure to the vaccine,
studies were conducted in relatively asymptomatic or mildly
symptomatic adults and children with HIV infection. These
studies demonstrated that LAIV was not associated with sig-
niﬁcant adverse events in HIV-infected individuals.
44,45 Sim-
ilarly, a recent comparative safety study conducted in 243
children 5–17 years of age with HIV disease (viral load
<60 000 and CD4 count >15%) demonstrated that there
were no unexpected toxicities, prolonged shedding, or seri-
ous adverse events associated with either LAIV or TIV.
46
Live attenuated vaccines against
pandemic inﬂuenza
The emergence and spread of highly pathogenic avian
inﬂuenza (HPAI) A/H5N1 viruses in avian populations
since 2003 and the concurrent infections in humans have
prompted efforts to develop vaccines for use in the event
of an inﬂuenza pandemic. Most pandemic inﬂuenza vac-
cines currently licensed or in development target the H5N1
subtype and are inactivated injectable vaccines administered
with or without adjuvant. It is important that every avenue
for vaccine development be explored as part of pandemic
preparedness activities. Live attenuated inﬂuenza vaccines
against potential pandemic inﬂuenza A viruses are being
developed in the United States and in Russia. Both
approaches capitalize on the use of the technology and
infrastructure already in place for seasonal LAIV, using
MDVs that display ts, ca, and att phenotypes. Based on the
experience with LAIV for seasonal inﬂuenza, it is reason-
able to expect that potential advantages of using live atten-
uated vaccines against pandemic inﬂuenza include rapid
induction of mucosal and systemic humoral and cell-medi-
ated immune responses and broad cross-protection against
antigenically distinct viruses.
In collaboration with MedImmune, the NIH (Bethesda,
MD, USA), is engaged in a program to develop candidate
pandemic LAIV (pLAIV) for use in the event of a pan-
demic. The candidate vaccines will be 6:2 reassortants,
generated by reverse genetics, with the HA and NA genes
of an inﬂuenza virus of pandemic potential, and the six
internal protein genes of the cold-adapted MDV-A virus.
The use of reverse genetics allows the removal of viru-
lence motifs such as the multibasic cleavage site in the
HA of HPAI viruses that is a known virulence factor in
poultry.
47 The candidate vaccines will be thoroughly char-
acterized in preclinical studies and evaluated for safety,
infectivity, and immunogenicity in phase I clinical trials
Table 5. Summary of solicited events observed within 7 days after
one dose of LAIV or placebo to adults 18–64 years of age (study
AV009)
Event, n/N (%)
LAIV
(n = 3264)
Placebo
(n = 1619)
Cough 426/3208 (13Æ3) 167/1589 (10Æ5)
Runny nose 1399/3208 (43Æ6) 429/1589 (27Æ0)
Sore throat 827/3208 (25Æ8) 262/1589 (16Æ5)
Headache 1165/2960 (39Æ4) 548/1476 (37Æ1)
Chills 258/3208 (8Æ0) 95/1589 (6Æ0)
Muscle aches 503/3208 (15Æ7) 228/1589 (14Æ3)
Tiredness/weakness 724/2960 (24Æ5) 304/1476 (20Æ6)
Fever
>100 F 42/3208 (1Æ3) 24/1589 (1Æ5)
>102 F 3/3208 (0Æ1) 2/1589 (0Æ1)
>104 F 0/3208 (0) 0/1589 (0)
LAIV, live attenuated inﬂuenza vaccine.
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inpatients at the Center for Immunization Research, Johns
Hopkins Bloomberg School of Public Health (Baltimore,
MD, USA). The studies will establish the proof of princi-
ple of the utility of such vaccines in the event of an inﬂu-
enza pandemic.
H5N1 pandemic LAIV
To date, NIH and MedImmune have generated three can-
didate pLAIV viruses of the H5N1 subtype that derive their
HA and NA from H5N1 inﬂuenza viruses isolated from
humans in Hong Kong in 1997, Hong Kong in 2003, and
Vietnam in 2004. In all cases, the HA was modiﬁed to
remove the multibasic cleavage site. As a result of this
modiﬁcation, all three vaccine viruses were of a low patho-
genicity phenotype in chickens. The vaccine viruses were
restricted in replication in the respiratory tract of mice and
attenuated in ferrets, consistent with the att phenotype of
the MDV. Toxicologic evaluation of H5N1 ca vaccine
viruses in ferrets revealed no evidence of systemic toxicity
following repeated intranasal administration.
48 Vaccination
with a single dose of H5N1 AA ca vaccine administered
intranasally protected mice against lethal challenge with
wild-type virus, but two doses administered intranasally
were required to elicit detectable serum HAI and neutraliz-
ing antibodies in mice and ferrets and to protect against
pulmonary replication of wild-type viruses.
49 In addition,
vaccination of mice with two doses of H5N1 ca vaccine
protected mice against pulmonary replication of antigeni-
cally distinct heterologous wild-type H5N1 viruses, suggest-
ing that such vaccines may elicit broadly cross-reactive
immune responses. The H5N1 pLAIV viruses with the HA
and NA from inﬂuenza A/Vietnam/1203/2004 (H5N1) and
inﬂuenza A/Hong Kong/213/2003 (H5N1) have been evalu-
ated for safety, infectivity, and immunogenicity in phase I
clinical trials (data on ﬁle).
Pandemic LAIV for other avian inﬂuenza
subtypes
Pandemic LAIV viruses for use against the avian inﬂu-
enza subtypes H9N2 and H7N3 have been generated and
characterized in preclinical studies. An H9N2 inﬂuenza
vaccine virus, which derived the HA and NA from the
low pathogenicity avian inﬂuenza isolate A/chicken/Hong
Kong/G9/1997 (H9N2), was generated by classical reas-
sortment. The H9N2 ca vaccine virus did not exhibit a
high pathogenicity phenotype in chickens, was restricted
in replication in the upper respiratory tract of mice, and
failed to replicate to detectable levels in the lower respi-
ratory tract of mice. Despite being restricted in replica-
tion, a single dose of the H9N2 ca vaccine administered
intranasally was immunogenic in mice and conferred
complete protection against replication of homologous
and heterologous wild-type H9N2 inﬂuenza viruses in the
upper and lower respiratory tract.
50 This vaccine virus
has been evaluated in phase I clinical trials.
51
An H7N3 candidate pLAIV that derived its HA and NA
from the low pathogenicity avian inﬂuenza H7N3 isolate
A/chicken/British Columbia/CN-6/2004 was generated by
reverse genetics. As with the previous avian inﬂuenza/AA
ca vaccine viruses, the H7N3 ca vaccine virus was exten-
sively characterized in pre-clinical studies
52 and was shown
to be safe for evaluation in phase I clinical trials (data on
ﬁle). Candidate vaccines for the other HA subtypes are cur-
rently in development.
Safety concerns with pandemic LAIV
viruses
The development of live attenuated viruses with the surface
glycoproteins of avian inﬂuenza viruses or other inﬂuenza
viruses of pandemic potential (e.g., H2 viruses) raises the
concern that these viruses may reassort with circulating
seasonal inﬂuenza viruses, and thereby generate easily
transmissible viruses with novel HA and NA. Although pre-
liminary data from clinical studies suggest that the pLAIV
viruses generated so far are highly restricted in replication,
this remains a signiﬁcant concern for regulatory authorities.
During development of these vaccines, the risk of reassort-
ment can be mitigated by conducting clinical trials in an
inpatient setting during months when inﬂuenza viruses are
not likely to be circulating. The clinical studies of pLAIV
viruses currently being conducted in the United States are
performed in an isolation facility between April and the
beginning of December. In the case of the threat of an
inﬂuenza pandemic, the risk of reassortment must be
weighed against the beneﬁts of administering such a vac-
cine to the population before proceeding with widespread
use of a live vaccine. Implementation of a live attenuated
pandemic inﬂuenza vaccine would be based on the recom-
mendation of public health authorities.
Acknowledgements
This research was supported in part by the Intramural
Research Program of the NIAID, NIH. The authors thank
Kanta Subbarao (NIH), and Robert Walker, Seth Toback,
Robert Fuentes, and Gregory Susla (MedImmune) for help-
ful discussion and review of the manuscript.
References
1 Maassab HF. Plaque formation of inﬂuenza virus at 25 degrees C.
Nature 1968; 219:645–646.
Ambrose et al.
ª 2008 Medlmmune
200 Journal Compilation ª 2008 Blackwell Publishing Ltd, Inﬂuenza and Other Respiratory Viruses, 2, 193–2022 Jin H, Lu B, Zhou H et al. Multiple amino acid residues confer tem-
perature sensitivity to human inﬂuenza virus vaccine strains (FluMist)
derived from cold-adapted A/Ann Arbor/6/60. Virology 2003;
306:18–24.
3 Jin H, Zhou H, Lu B, Kemble G. Imparting temperature sensitivity
and attenuation in ferrets to A/Puerto Rico/8/34 inﬂuenza virus by
transferring the genetic signature for temperature sensitivity from
cold-adapted A/Ann Arbor/6/60. J Virol 2004; 78:995–998.
4 Chen Z, Aspelund A, Kemble G, Jin H. Genetic mapping of the
cold-adapted phenotype of B/Ann Arbor/1/66, the master donor
virus for live attenuated inﬂuenza vaccines (FluMist). Virology 2006;
345:416–423.
5 Hoffmann E, Mahmood K, Chen Z et al. Multiple gene segments
control the temperature sensitivity and attenuation phenotypes of
ca B/Ann Arbor/1/66. J Virol 2005; 79:11014–11021.
6 Kemble G, Greenberg H. Novel generations of inﬂuenza vaccines.
Vaccine 2003; 21:1789–1795.
7 Murphy BR, Coelingh K. Principles underlying the development and
use of live attenuated cold-adapted inﬂuenza A and B virus vac-
cines. Viral Immunol 2002; 15:295–323.
8 Smith DB, Inglis SC. The mutation rate and variability of eukaryotic
viruses: an analytical review. J Gen Virol 1987; 68 (Pt 11):2729–
2740.
9 Vesikari T, Karvonen A, Korhonen T et al. A randomized double-
blind study of the safety, transmissibility, and phenotypic and geno-
typic stability of cold-adapted inﬂuenza virus vaccine (LAIV, Flu-
Mist
 ). Pediatr Infect Dis J 2006; 25:590–595.
10 Gruber WC. The role of live inﬂuenza vaccines in children. Vaccine
2002; 20:S66–S73.
11 Belshe RB, Mendelman PM, Treanor J et al. The efﬁcacy of live
attenuated, cold-adapted, trivalent, intranasal inﬂuenza virus vac-
cine in children. N Engl J Med 1998; 338:1405–1412.
12 Belshe RB, Gruber WC. Prevention of otitis media in children with
live attenuated inﬂuenza vaccine given intranasally. Pediatr Infect
Dis J 2000; 19:S66–S71.
13 Bracco Neto H, Farhat CK, Tregnaghi MW et al. Efﬁcacy and safety
of one and two doses of live attenuated inﬂuenza vaccine in
vaccine-naive children. Pediatr Infect Dis J 2009 (in press).
14 Belshe RB, Gruber WC, Mendelman PM et al. Efﬁcacy of vaccina-
tion with live attenuated, cold-adapted, trivalent, intranasal inﬂu-
enza virus vaccine against a variant (A/Sydney) not contained in the
vaccine. J Pediatr 2000; 136:168–175.
15 Gaglani MJ, Piedra PA, Herschler GB et al. Direct and total effec-
tiveness of the intranasal, live-attenuated, trivalent cold-adapted
inﬂuenza virus vaccine against the 2000-2001 inﬂuenza A(H1N1)
and B epidemic in healthy children. Arch Pediatr Adolesc Med
2004; 158:65–73.
16 Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efﬁcacy of
trivalent, cold-adapted, inﬂuenza virus vaccine (CAIV-T) against
inﬂuenza A (H1N1) and B using surveillance cultures. Am J Epidemi-
ol 2003; 158:305–311.
17 Halloran ME, Piedra PA, Longini IM Jr et al. Efﬁcacy of trivalent,
cold-adapted, inﬂuenza virus vaccine against inﬂuenza A (Fujian), a
drift variant, during 2003-2004. Vaccine 2007; 25:4038–4045.
18 Tam JS, Capeding MR, Lum LC et al. Efﬁcacy and safety of a live
attenuated, cold-adapted inﬂuenza vaccine, trivalent against cul-
ture-conﬁrmed inﬂuenza in young children in Asia. Pediatr Infect
Dis J 2007; 26:619–628.
19 Jackson LA, Neuzil KM, Baggs J et al. Compliance with the recom-
mendations for 2 doses of trivalent inactivated inﬂuenza vaccine in
children less than 9 years of age receiving inﬂuenza vaccine for the
ﬁrst time: a Vaccine Safety Datalink study. Pediatrics 2006;
118:2032–2037.
20 Ashkenazi S, Vertruyen A, Aristegui J et al. Superior relative efﬁcacy
of live attenuated inﬂuenza vaccine compared with inactivated
inﬂuenza vaccine in young children with recurrent respiratory tract
infections. Pediatr Infect Dis J 2006; 25:870–879.
21 Fleming DM, Crovari P, Wahn U et al. Comparison of the efﬁcacy
and safety of live attenuated cold-adapted inﬂuenza vaccine, triva-
lent, with trivalent inactivated inﬂuenza virus vaccine in children
and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860–
869.
22 Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus
inactivated inﬂuenza vaccine in infants and young children. N Engl J
Med 2007; 356:685–696.
23 FluMist
 , Inﬂuenza Virus Vaccine Live, Intranasal. Full Prescribing
Information, Gaithersburg, MD: MedImmune, 2007.
24 Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live,
attenuated intranasal inﬂuenza virus vaccine in healthy, working
adults: a randomized controlled trial. JAMA 1999; 282:137–144.
25 Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and
cost-beneﬁt of inﬂuenza vaccination of healthy working adults: a
randomized controlled trial. JAMA 2000; 284:1655–1663.
26 Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live,
cold-adapted (CAIV-T) and inactivated (TIV) inﬂuenza vaccines in
prevention of virus infection and illness following challenge of
adults with wild-type inﬂuenza A (H1N1), A (H3N2), and B viruses.
Vaccine 1999; 18:899–906.
27 Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically
drifted inﬂuenza by inactivated and live attenuated vaccines. N Engl
J Med 2006; 355:2513–2522.
28 Boyce TG. Inﬂuenza vaccines. N Engl J Med 2007; 356:1172; author
reply 1173.
29 Lin YP, Gregory V, Bennett M, Hay A. Recent changes among
human inﬂuenza viruses. Virus Res 2004; 103:47–52.
30 Ohmit SE, Victor JC, Teich ER et al. Prevention of symptomatic sea-
sonal inﬂuenza in 2005-2006 by inactivated and live attenuated
vaccines. J Infect Dis 2008; 198:312–317.
31 Strickler JK, Hawksworth AW, Myers C, Irvine M, Ryan MA,
Russell KL. Inﬂuenza vaccine effectiveness among US military
basic trainees, 2005-06 season. Emerg Infect Dis 2007; 13:617–
619.
32 de Villiers PJT, Greyling M, Taylor CM et al. Efﬁcacy of a live, atten-
uated, inﬂuenza vaccine in South African adults aged 60 years or
older against community-acquired culture-conﬁrmed inﬂuenza.
Options for the Control of Inﬂuenza, 5th International Conference,
October 7–11, 2003, Okinawa, Japan.
33 Data on File (Study D153-P516). Gaithersburg, MD: MedImmune,
2006.
34 Treanor JJ, Mattison HR, Dumyati G et al. Protective efﬁcacy of
combined live intranasal and inactivated inﬂuenza A virus vaccines
in the elderly. Ann Intern Med 1992; 117:625–633.
35 Treanor JJ, Betts RF. Evaluation of live, cold-adapted inﬂuenza A
and B virus vaccines in elderly and high-risk subjects. Vaccine 1998;
16:1756–1760.
36 Gorse GJ, O’Connor TZ, Young SL et al. Efﬁcacy trial of live, cold-
adapted and inactivated inﬂuenza virus vaccines in older adults with
chronic obstructive pulmonary disease: a VA cooperative study. Vac-
cine 2003; 21:2133–2144.
37 Gorse GJ, O’Connor TZ, Young SL et al. Impact of a winter respira-
tory virus season on patients with COPD and association with inﬂu-
enza vaccination. Chest 2006; 130:1109–1116.
38 Forrest BD, Pride MW, Dunning AJ et al. Correlation of cellular
immune responses with protection against culture-conﬁrmed inﬂu-
enza virus in young children. Clin Vaccine Immunol 2008; 15:1042–
1053.
Seasonal and pandemic LAIV
ª 2008 Medlmmune
Journal Compilation ª 2008 Blackwell Publishing Ltd, Inﬂuenza and Other Respiratory Viruses, 2, 193–202 20139 Vesikari T, Fleming DM, Aristegui JF et al. Safety, efﬁcacy, and
effectiveness of cold-adapted inﬂuenza vaccine-trivalent against
community-acquired, culture-conﬁrmed inﬂuenza in young children
attending day care. Pediatrics 2006; 118:2298–2312.
40 Belshe RB, Gruber WC, Mendelman PM et al. Correlates of
immune protection induced by live, attenuated, cold-adapted, tri-
valent, intranasal inﬂuenza virus vaccine. J Infect Dis 2000;
181:1133–1137.
41 Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer
PS, Wright PF. A randomized controlled trial of cold-adapted and
inactivated vaccines for the prevention of inﬂuenza A disease. J
Infect Dis 1994; 169:68–76.
42 Block SL, Reisinger KS, for the LAIV Study Group. Shedding and
safety of live attenuated inﬂuenza vaccine in healthy subjects 6 to
<60 months of age. Pediatric Academic Societies’ Annual Meeting,
May 2–6, 2008, Honolulu, HI.
43 Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE.
Shedding and immunogenicity of live attenuated inﬂuenza vaccine
virus in subjects 5 to 49 years of age. Vaccine 2008; 26:4940–
4946.
44 King JC Jr, Fast PE, Zangwill KM et al. Safety, vaccine virus shed-
ding and immunogenicity of trivalent, cold-adapted, live attenuated
inﬂuenza vaccine administered to human immunodeﬁciency virus-
infected and noninfected children. Pediatr Infect Dis J 2001;
20:1124–1131.
45 King JC Jr, Treanor J, Fast PE et al. Comparison of the safety, vac-
cine virus shedding, and immunogenicity of inﬂuenza virus vaccine,
trivalent, types A and B, live cold-adapted, administered to human
immunodeﬁciency virus (HIV)-infected and non-HIV-infected adults.
J Infect Dis 2000; 181:725–728.
46 Levin MJ, Song LY, Fenton T et al. Shedding of live vaccine virus,
comparative safety, and inﬂuenza-speciﬁc antibody responses after
administration of live attenuated and inactivated trivalent inﬂuenza
vaccines to HIV-infected children. Vaccine 2008; 26:4210–4217.
47 Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence
for a correlation of hemagglutinin cleavability and virulence of an
avian inﬂuenza A virus. J Virol 1994; 68:3120–3128.
48 Jin H, Manetz S, Leininger J et al. Toxicological evaluation of live
attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 2007;
25:8664–8672.
49 Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated inﬂu-
enza A H5N1 candidate vaccines provide broad cross-protection in
mice and ferrets. PLoS Med 2006; 3:e360.
50 Chen H, Matsuoka Y, Swayne D et al. Generation and characteriza-
tion of a cold-adapted inﬂuenza A H9N2 reassortant as a live
pandemic inﬂuenza virus vaccine candidate. Vaccine 2003;
21:4430–4436.
51 Karron RA, Callahan K, Luke C et al. A live attenuated H9N2 inﬂu-
enza vaccine is well-tolerated and immunogenic in healthy adults.
J Infect Dis 2008 (in press).
52 Joseph T, McAuliffe J, Lu B et al. A live attenuated cold-adapted
inﬂuenza A H7N3 virus vaccine provides protection against homolo-
gous and heterologous H7 viruses in mice and ferrets. Virology
2008; 378:123–132.
53 Lum LCS, Forrest BD, The LAIV Concomitant Vaccine Study Group.
Safety, efﬁcacy, and immunogenicity of live attenuated inﬂuenza
vaccine concurrently administered with a combination mumps,
measles, and rubella vaccine. 26th Annual Meeting of the European
Society for Paediatric Infectious Diseases, May 13–17, 2008, Graz,
Austria.
Ambrose et al.
ª 2008 Medlmmune
202 Journal Compilation ª 2008 Blackwell Publishing Ltd, Inﬂuenza and Other Respiratory Viruses, 2, 193–202